Translate AMICOR contents if you like

Tuesday, November 30, 2010

Alzheimer's disease: Revising Definition

The Lancet Neurology, Volume 9, Issue 11, Pages 1118 - 1127, November 2010
doi:10.1016/S1474-4422(10)70223-4Cite or Link Using DOI
Published Online: 11 October 2010

Revising the definition of Alzheimer's disease: a new lexicon

Prof Bruno Dubois MD a Corresponding AuthorEmail AddressProf Howard H Feldman MD b c dClaudia Jacova PhD bJeffrey L Cummings MD eProf Steven T DeKosky MD fPascale Barberger-Gateau MD gAndré Delacourte PhD hProf Giovanni Frisoni MD iProf Nick C Fox MD j*ProfDouglas Galasko MD kProf Serge Gauthier MD lProf Harald Hampel MD mGregory A Jicha MD nKenichi Meguro MD oJohn O'Brien DM pProf Florence Pasquier MD qProf Philippe Robert MD rProf Martin Rossor MD jProf Steven Salloway MD sMarie Sarazin MD aLeonardo C de Souza MD aProf Yaakov Stern PhD tPieter J Visser MD u vProf Philip Scheltens MD v

Summary

Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The recent advances in use of reliable biomarkers of AD that provide in-vivo evidence of the disease has stimulated the development of new research criteria that reconceptualise the diagnosis around both a specific pattern of cognitive changes and structural/biological evidence of Alzheimer's pathology. This new diagnostic framework has stimulated debate about the definition of AD and related conditions. The potential for drugs to intercede in the pathogenic cascade of the disease adds some urgency to this debate. This paper by the International Working Group for New Research Criteria for the Diagnosis of AD aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities. The cornerstone of this lexicon is to consider AD solely as a clinical and symptomatic entity that encompasses both predementia and dementia phases./.../

No comments: